Distribution expansion , commercial agreements , approvals , awareness , trial data is the major focus here and sales are just a bonus. This is being set up to look as enticing as possible. A large pharma could monetize this much better than oncosil ever could and I think they know it.
The stock price and market cap decimation has provided large pharma's an opportunity to take over oncosil with what would be considered chump change to them. Market Cap vs Options for Pancreatic Cancer vs Recent Data released make this even more enticing.
OncoSil's cancer device shows shrink in pancreatic tumours
OncoSil Medical (ASX:OSL) released groundbreaking findings from a study which showed that the addition of OncoSil™ to systemic chemotherapy returned an increase in the vascularity of the primary pancreatic tumors, and at the same time: resulted in a significant decrease in the size of tumours.
The study, conducted at the Royal Adelaide Hospital in South Australia, involved patients with locally advanced pancreatic cancer undergoing chemotherapy plus OncoSil™ implantation. Results showed a substantial increase in tumor vascularity at 4 and 12 weeks post-implantation, indicating a positive response to treatment. Additionally, the size of primary tumors decreased significantly following OncoSil™ implantation, further demonstrating the effectiveness of the treatment.
Researchers found that adding OncoSil™ to standard chemotherapy led to a significant increase in tumor vascularity, accompanied by a notable decrease in tumor size. this is the first study to show that the poor blood supply to pancreatic tumors can be improved. At 12 weeks following OncoSil™ implantation, the local disease control rate was 100%. To date, 5 patients (25%) had their tumors downstaged, with 3 patients undergoing surgical resection to remove the primary tumor, another patient with surgery pending and one patient having refused surgical treatment.
Expand
(20min delay)